News Related to ALX2004

Related coverage linked through entity extraction aliases.

ALX Oncology sets 2026 data milestones for Evorpacept and ALX2004

Apr 08, 2026

ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.

ALX Oncology Reports 2025 Results, Advances Evorpacept and ALX2004 Clinical Programs

Feb 27, 2026

ALX Oncology reported fourth quarter and full year 2025 financial results, highlighting validation of CD47 as a predictive biomarker for evorpacept in HER2-positive cancers and progress in its ALX2004 EGFR-targeted ADC program.